Income Statement Agilent Technologies, Inc.
Equities
A
US00846U1016
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113.43 USD | +0.43% |
|
-6.49% | -15.56% |
Fiscal Period: October | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 5.34B | 6.32B | 6.85B | 6.83B | 6.51B | |||||
Total Revenues | 5.34B | 6.32B | 6.85B | 6.83B | 6.51B | |||||
Cost of Goods Sold, Total | 2.5B | 2.91B | 3.13B | 3.37B | 2.98B | |||||
Gross Profit | 2.84B | 3.41B | 3.72B | 3.46B | 3.54B | |||||
Selling General & Admin Expenses, Total | 1.4B | 1.56B | 1.58B | 1.58B | 1.52B | |||||
R&D Expenses | 397M | 441M | 467M | 481M | 473M | |||||
Other Operating Expenses, Total | 1.79B | 2B | 2.04B | 2.06B | 1.99B | |||||
Operating Income | 1.04B | 1.4B | 1.68B | 1.41B | 1.54B | |||||
Interest Expense, Total | -78M | -81M | -84M | -95M | -96M | |||||
Interest And Investment Income | 8M | 2M | 9M | 51M | 80M | |||||
Net Interest Expenses | -70M | -79M | -75M | -44M | -16M | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | -4M | -4M | -6M | -2M | -4M | |||||
Other Non Operating Income (Expenses) | 15M | 15M | 14M | 62M | 20M | |||||
EBT, Excl. Unusual Items | 986M | 1.34B | 1.61B | 1.42B | 1.54B | |||||
Restructuring Charges | -151M | -37M | -30M | -25M | -11M | |||||
Merger & Related Restructuring Charges | -41M | -41M | -25M | -16M | -12M | |||||
Gain (Loss) On Sale Of Investments | 26M | 98M | -67M | -41M | 6M | |||||
Asset Writedown | - | - | - | - | -6M | |||||
Legal Settlements | 22M | - | - | - | - | |||||
Other Unusual Items | - | 4M | 16M | -1M | - | |||||
EBT, Incl. Unusual Items | 842M | 1.36B | 1.5B | 1.34B | 1.52B | |||||
Income Tax Expense | 123M | 150M | 250M | 99M | 232M | |||||
Earnings From Continuing Operations | 719M | 1.21B | 1.25B | 1.24B | 1.29B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 719M | 1.21B | 1.25B | 1.24B | 1.29B | |||||
Net Income - (IS) | 719M | 1.21B | 1.25B | 1.24B | 1.29B | |||||
Net Income to Common Incl Extra Items | 719M | 1.21B | 1.25B | 1.24B | 1.29B | |||||
Net Income to Common Excl. Extra Items | 719M | 1.21B | 1.25B | 1.24B | 1.29B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.33 | 3.98 | 4.19 | 4.22 | 4.44 | |||||
Basic EPS - Continuing Operations | 2.33 | 3.98 | 4.19 | 4.22 | 4.44 | |||||
Basic Weighted Average Shares Outstanding | 309M | 304M | 299M | 294M | 290M | |||||
Net EPS - Diluted | 2.3 | 3.94 | 4.18 | 4.19 | 4.43 | |||||
Diluted EPS - Continuing Operations | 2.3 | 3.94 | 4.18 | 4.19 | 4.43 | |||||
Diluted Weighted Average Shares Outstanding | 312M | 307M | 300M | 296M | 291M | |||||
Normalized Basic EPS | 1.99 | 2.75 | 3.37 | 3.02 | 3.33 | |||||
Normalized Diluted EPS | 1.98 | 2.72 | 3.35 | 3 | 3.32 | |||||
Dividend Per Share | 0.72 | 0.78 | 0.84 | 0.9 | 0.94 | |||||
Payout Ratio | 30.88 | 19.5 | 19.94 | 21.37 | 21.26 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.35B | 1.72B | 1.99B | 1.68B | 1.8B | |||||
EBITA | 1.23B | 1.6B | 1.87B | 1.55B | 1.65B | |||||
EBIT | 1.04B | 1.4B | 1.68B | 1.41B | 1.54B | |||||
EBITDAR | 1.41B | 1.79B | 2.06B | 1.75B | 1.86B | |||||
Total Revenues (As Reported) | 5.34B | 6.32B | 6.85B | 6.83B | 6.51B | |||||
Effective Tax Rate - (Ratio) | 14.61 | 11.03 | 16.62 | 7.39 | 15.25 | |||||
Current Domestic Taxes | 10M | 139M | 195M | 129M | 209M | |||||
Current Foreign Taxes | 84M | -3M | 47M | 26M | 87M | |||||
Total Current Taxes | 94M | 136M | 242M | 155M | 296M | |||||
Deferred Domestic Taxes | 5M | 0 | -27M | -94M | -124M | |||||
Deferred Foreign Taxes | 24M | 14M | 35M | 38M | 60M | |||||
Total Deferred Taxes | 29M | 14M | 8M | -56M | -64M | |||||
Normalized Net Income | 616M | 835M | 1.01B | 889M | 965M | |||||
Interest on Long-Term Debt | 78M | 81M | 84M | - | - | |||||
Non-Cash Pension Expense | 4M | 2M | -18M | -8M | -23M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 48M | 63M | 66M | 54M | 49M | |||||
Selling and Marketing Expenses | - | - | - | - | 49M | |||||
Research And Development Expense From Footnotes | 495M | 441M | 467M | 481M | 479M | |||||
Net Rental Expense, Total | 61M | 62M | 62M | 70M | 56M | |||||
Imputed Operating Lease Interest Expense | 15.4M | 14.75M | 14.29M | 18.28M | 13.29M | |||||
Imputed Operating Lease Depreciation | 45.6M | 47.25M | 47.71M | 51.72M | 42.71M | |||||
Stock-Based Comp., COGS (Total) | 21M | 26M | 30M | 34M | 41M | |||||
Stock-Based Comp., R&D Exp. (Total) | 9M | 12M | 14M | 13M | 16M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 54M | 73M | 82M | 65M | 73M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 84M | 111M | 126M | 112M | 130M |
- Stock Market
- Equities
- A Stock
- Financials Agilent Technologies, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions